LogicBio Therapeutics Inc
NASDAQ:LOGC
LogicBio Therapeutics Inc
Accounts Payable
LogicBio Therapeutics Inc
Accounts Payable Peer Comparison
Competitive Accounts Payable Analysis
Latest Figures & CAGR of Competitors
Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
LogicBio Therapeutics Inc
NASDAQ:LOGC
|
Accounts Payable
$718k
|
CAGR 3-Years
-15%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Accounts Payable
$31.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
22%
|
CAGR 10-Years
18%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accounts Payable
$622m
|
CAGR 3-Years
3%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Accounts Payable
$1.6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
8%
|
CAGR 10-Years
6%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accounts Payable
$351.4m
|
CAGR 3-Years
40%
|
CAGR 5-Years
34%
|
CAGR 10-Years
22%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accounts Payable
$671.3m
|
CAGR 3-Years
7%
|
CAGR 5-Years
23%
|
CAGR 10-Years
35%
|
See Also
What is LogicBio Therapeutics Inc's Accounts Payable?
Accounts Payable
718k
USD
Based on the financial report for Dec 31, 2021, LogicBio Therapeutics Inc's Accounts Payable amounts to 718k USD.
What is LogicBio Therapeutics Inc's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
16%
Over the last year, the Accounts Payable growth was 60%. The average annual Accounts Payable growth rates for LogicBio Therapeutics Inc have been -15% over the past three years , 16% over the past five years .